{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:47:02Z","timestamp":1793641622611,"version":"4.5.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41409-018-0307-1","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T13:53:32Z","timestamp":1534427612000},"page":"681-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Methods and role of minimal residual disease after stem cell transplantation"],"prefix":"10.1038","volume":"54","author":[{"given":"Marco","family":"Ladetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"307_CR1","first-page":"676","volume":"11","author":"HF Bisel","year":"1956","unstructured":"Bisel HF. Criteria for the evaluation of response to treatment in acute leukemia. Blood. 1956;11:676\u20137.","journal-title":"Blood"},{"key":"307_CR2","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/leu.2017.113","volume":"31","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482\u201390. \n                    https:\/\/doi.org\/10.1038\/leu.2017.113","journal-title":"Leukemia"},{"issue":"4","key":"307_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1080\/10428194.2017.1361023","volume":"59","author":"Nicole M. Cruz","year":"2017","unstructured":"Cruz NM, Sugita M, Ewing-Crystal N, Lam L, Galetto R, Gouble A et al. Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. Leuk Lymphoma. 2017: 1\u20135. \n                    https:\/\/doi.org\/10.1080\/10428194.2017.1361023","journal-title":"Leukemia & Lymphoma"},{"key":"307_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391. \n                    https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"307_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/blood-2011-08-363291","volume":"119","author":"F Buccisano","year":"2012","unstructured":"Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119:332\u201341. \n                    https:\/\/doi.org\/10.1182\/blood-2011-08-363291","journal-title":"Blood"},{"key":"307_CR6","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","volume":"120","author":"JA Yin","year":"2012","unstructured":"Yin JA, O\u2019Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826\u201335. \n                    https:\/\/doi.org\/10.1182\/blood-2012-06-435669","journal-title":"Blood"},{"key":"307_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422\u201333. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1507471","journal-title":"N Engl J Med"},{"key":"307_CR8","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","volume":"29","author":"J Kronke","year":"2011","unstructured":"Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German\u2013Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29:2709\u201316. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.35.0371","journal-title":"J Clin Oncol"},{"key":"307_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","volume":"122","author":"N Shayegi","year":"2013","unstructured":"Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013;122:83\u201392. \n                    https:\/\/doi.org\/10.1182\/blood-2012-10-461749","journal-title":"Blood"},{"key":"307_CR10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","volume":"33","author":"X Chen","year":"2015","unstructured":"Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258\u201364. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.58.3518","journal-title":"J Clin Oncol"},{"key":"307_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190\u20137. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.31.8121","journal-title":"J Clin Oncol"},{"issue":"7","key":"307_CR12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.bbmt.2018.02.003","volume":"24","author":"Mithun Vinod Shah","year":"2018","unstructured":"Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS et al. Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia. Biol Blood Marrow Transplant. 2018. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.003","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"307_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2016.144253","volume":"102","author":"B Oran","year":"2017","unstructured":"Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, et al. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017;102:110\u20137. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.144253","journal-title":"Haematologica"},{"key":"307_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"M Balsat","year":"2017","unstructured":"Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia french association group. J Clin Oncol. 2017;35:185\u201393. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.67.1875","journal-title":"J Clin Oncol"},{"key":"307_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.46","volume":"6","author":"S Kayser","year":"2016","unstructured":"Kayser S, Benner A, Thiede C, Martens U, Huber J, Stadtherr P, et al. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 2016;6:e449 \n                    https:\/\/doi.org\/10.1038\/bcj.2016.46","journal-title":"Blood Cancer J"},{"key":"307_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.exphem.2008.09.014","volume":"37","author":"U Bacher","year":"2009","unstructured":"Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kroger N. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol. 2009;37:135\u201342. \n                    https:\/\/doi.org\/10.1016\/j.exphem.2008.09.014","journal-title":"Exp Hematol"},{"key":"307_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.leukres.2011.11.002","volume":"36","author":"E Abdelhamid","year":"2012","unstructured":"Abdelhamid E, Preudhomme C, Helevaut N, Nibourel O, Gardin C, Rousselot P, et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res. 2012;36:316\u201323. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2011.11.002","journal-title":"Leuk Res"},{"key":"307_CR18","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.bbmt.2014.08.015","volume":"20","author":"MR Grunwald","year":"2014","unstructured":"Grunwald MR, Tseng LH, Lin MT, Pratz KW, Eshleman JR, Levis MJ, et al. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20:1989\u201395. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2014.08.015","journal-title":"Biol Blood Marrow Transplant"},{"key":"307_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cancergen.2012.02.008","volume":"205","author":"JM Alonso-Dominguez","year":"2012","unstructured":"Alonso-Dominguez JM, Tenorio M, Velasco D, Abalo L, Lozano S, Villarrubia J, et al. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genet. 2012;205:190\u20131. \n                    https:\/\/doi.org\/10.1016\/j.cancergen.2012.02.008","journal-title":"Cancer Genet"},{"issue":"11","key":"307_CR20","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.bbmt.2018.05.011","volume":"24","author":"Christina Rautenberg","year":"2018","unstructured":"Rautenberg C, Pechtel S, Hildebrandt B, Betz B, Dienst A, Nachtkamp K et al. Wilms\u2019 tumor 1 (WT1) expression using a standardized european leukemia net-certified assay compared to other methods for detection of minimal residual disease in MDS and AML patients after allogeneic blood stem cell transplantation. Biol Blood Marrow Transplant 2018. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.011","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"307_CR21","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","volume":"121","author":"HH Zhu","year":"2013","unstructured":"Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121:4056\u201362. \n                    https:\/\/doi.org\/10.1182\/blood-2012-11-468348","journal-title":"Blood"},{"key":"307_CR22","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, et al. In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood. 2014;124:1880\u20136. \n                    https:\/\/doi.org\/10.1182\/blood-2014-03-563403","journal-title":"Blood"},{"key":"307_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nmeth.2633","volume":"10","author":"CM Hindson","year":"2013","unstructured":"Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013;10:1003\u20135. \n                    https:\/\/doi.org\/10.1038\/nmeth.2633","journal-title":"Nat Methods"},{"key":"307_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1521-6926(03)00067-7","volume":"16","author":"MB Vidriales","year":"2003","unstructured":"Vidriales MB, San-Miguel JF, Orfao A, Coustan-Smith E, Campana D. Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol. 2003;16:599\u2013612.","journal-title":"Best Pract Res Clin Haematol"},{"key":"307_CR25","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/bmt.2014.99","volume":"4","author":"JM Jaso","year":"2014","unstructured":"Jaso JM, Wang SA, Jorgensen JL, Lin P. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant. 2014;4:1129\u201338. \n                    https:\/\/doi.org\/10.1038\/bmt.2014.99","journal-title":"Bone Marrow Transplant"},{"key":"307_CR26","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","volume":"20","author":"F Buccisano","year":"2006","unstructured":"Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006;20:1783\u20139. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404313","journal-title":"Leukemia"},{"key":"307_CR27","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood.V98.6.1746","volume":"98","author":"JF San Miguel","year":"2001","unstructured":"San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746\u201351.","journal-title":"Blood"},{"key":"307_CR28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/gcc.22375","volume":"55","author":"L Pettersson","year":"2016","unstructured":"Pettersson L, Leveen P, Axler O, Dvorakova D, Juliusson G, Ehinger M. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. Genes Chromosomes Cancer. 2016;55:750\u201366. \n                    https:\/\/doi.org\/10.1002\/gcc.22375","journal-title":"Genes Chromosomes Cancer"},{"key":"307_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/1097-0320(20000815)42:4<247::AID-CYTO5>3.0.CO;2-V","volume":"42","author":"U Oelschlagel","year":"2000","unstructured":"Oelschlagel U, Nowak R, Schaub A, Koppel C, Herbst R, Mohr B, et al. Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia. Cytometry. 2000;42:247\u201353.","journal-title":"Cytometry"},{"key":"307_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/gcc.21955","volume":"51","author":"F Thol","year":"2012","unstructured":"Thol F, Kolking B, Damm F, Reinhardt K, Klusmann JH, Reinhardt D, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012;51:689\u201395. \n                    https:\/\/doi.org\/10.1002\/gcc.21955","journal-title":"Genes Chromosomes Cancer"},{"key":"307_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/leu.2013.239","volume":"28","author":"A Kohlmann","year":"2014","unstructured":"Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia. 2014;28:129\u201337. \n                    https:\/\/doi.org\/10.1038\/leu.2013.239","journal-title":"Leukemia"},{"key":"307_CR32","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","volume":"124","author":"D Grimwade","year":"2014","unstructured":"Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d. Blood. 2014;124:3345\u201355. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-577593","journal-title":"Blood"},{"key":"307_CR33","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/nar\/gkt692","volume":"41","author":"CR Cabanski","year":"2013","unstructured":"Cabanski CR, Wilkerson MD, Soloway M, Parker JS, Liu J, Prins JF, et al. BlackOPs: increasing confidence in variant detection through mappability filtering. Nucleic Acids Res. 2013;41:e178 \n                    https:\/\/doi.org\/10.1093\/nar\/gkt692","journal-title":"Nucleic Acids Res"},{"key":"307_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.bbmt.2015.10.024","volume":"22","author":"C Ustun","year":"2016","unstructured":"Ustun C, Courville EL, DeFor T, Dolan M, Randall N, Yohe S, et al. Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia. Biol Blood Marrow Transplant. 2016;22:669\u201375. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.024","journal-title":"Biol Blood Marrow Transplant"},{"key":"307_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26:381\u20139. \n                    https:\/\/doi.org\/10.1038\/leu.2011.234","journal-title":"Leukemia"},{"key":"307_CR36","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138. \n                    https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"307_CR37","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-14-2841","volume":"21","author":"B Paiva","year":"2015","unstructured":"Paiva B, Puig N, Garcia-Sanz R, San Miguel JF. Grupo Espanol de Mieloma \/Programa para el Estudio de la Terapeutica en Hemopatias Malignas cooperative study g. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res. 2015;21:2001\u20138. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2841","journal-title":"Clin Cancer Res"},{"key":"307_CR38","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540\u20137. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.46.2119","journal-title":"J Clin Oncol"},{"key":"307_CR39","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","volume":"29","author":"B Paiva","year":"2011","unstructured":"Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29:1627\u201333. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.33.1967","journal-title":"J Clin Oncol"},{"key":"307_CR40","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","volume":"112","author":"B Paiva","year":"2008","unstructured":"Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017\u201323. \n                    https:\/\/doi.org\/10.1182\/blood-2008-05-159624","journal-title":"Blood"},{"key":"307_CR41","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/leu.2012.121","volume":"26","author":"JJ Dongen van","year":"2012","unstructured":"van Dongen JJ, Orfao A, EuroFlow C. EuroFlow: resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia. 2012;26:1899\u2013907. \n                    https:\/\/doi.org\/10.1038\/leu.2012.121","journal-title":"Leukemia"},{"key":"307_CR42","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103. \n                    https:\/\/doi.org\/10.1038\/leu.2017.29","journal-title":"Leukemia"},{"key":"307_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","volume":"6","author":"M Ladetto","year":"2000","unstructured":"Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R, et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant. 2000;6:241\u201353.","journal-title":"Biol Blood Marrow Transplant"},{"key":"307_CR44","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","volume":"17","author":"D Drandi","year":"2015","unstructured":"Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, et al. Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn. 2015;17:652\u201360. \n                    https:\/\/doi.org\/10.1016\/j.jmoldx.2015.05.007","journal-title":"J Mol Diagn"},{"key":"307_CR45","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","volume":"28","author":"M Ladetto","year":"2014","unstructured":"Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299\u2013307. \n                    https:\/\/doi.org\/10.1038\/leu.2013.375","journal-title":"Leukemia"},{"key":"307_CR46","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073\u20139. \n                    https:\/\/doi.org\/10.1182\/blood-2014-01-550020","journal-title":"Blood"},{"key":"307_CR47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/leu.2014.219","volume":"29","author":"S Ferrero","year":"2015","unstructured":"Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics\u2019 impact on survival. Leukemia. 2015;29:689\u201395. \n                    https:\/\/doi.org\/10.1038\/leu.2014.219","journal-title":"Leukemia"},{"key":"307_CR48","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1365-2141.2008.07263.x","volume":"142","author":"P Martinez-Sanchez","year":"2008","unstructured":"Martinez-Sanchez P, Montejano L, Sarasquete ME, Garcia-Sanz R, Fernandez-Redondo E, Ayala R, et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol. 2008;142:766\u201374. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07263.x","journal-title":"Br J Haematol"},{"key":"307_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.1999.17.1.208","volume":"17","author":"P Corradini","year":"1999","unstructured":"Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999;17:208\u201315. \n                    https:\/\/doi.org\/10.1200\/JCO.1999.17.1.208","journal-title":"J Clin Oncol"},{"key":"307_CR50","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","volume":"28","author":"M Ladetto","year":"2010","unstructured":"Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28:2077\u201384. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.7172","journal-title":"J Clin Oncol"},{"key":"307_CR51","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2015.269","volume":"30","author":"M Ladetto","year":"2016","unstructured":"Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia. 2016;30:1211\u20134. \n                    https:\/\/doi.org\/10.1038\/leu.2015.269","journal-title":"Leukemia"},{"key":"307_CR52","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.leukres.2005.01.017","volume":"29","author":"S Galimberti","year":"2005","unstructured":"Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2005;29:961\u20136. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2005.01.017","journal-title":"Leuk Res"},{"key":"307_CR53","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/annonc\/mdi123","volume":"16","author":"MS Raab","year":"2005","unstructured":"Raab MS, Cremer FW, Breitkreutz IN, Gerull S, Luft T, Benner A, et al. Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Ann Oncol. 2005;16:611\u20137. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdi123","journal-title":"Ann Oncol"},{"key":"307_CR54","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","volume":"37","author":"N Kroger","year":"2009","unstructured":"Kroger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37:791\u20138. \n                    https:\/\/doi.org\/10.1016\/j.exphem.2009.03.008","journal-title":"Exp Hematol"},{"key":"307_CR55","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"307_CR56","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH Velden van der","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia"},{"key":"307_CR57","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: a European Research Initiative on CLL study. Leukemia. 2016;30:929\u201336. \n                    https:\/\/doi.org\/10.1038\/leu.2015.313\n                    \n                  . E-pub ahead of print 2015\/12\/08","journal-title":"Leukemia"},{"key":"307_CR58","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956\u201364. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404584\n                    \n                  . E-pub ahead of print 2007\/03\/16","journal-title":"Leukemia"},{"issue":"9","key":"307_CR59","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986\u20132010.","journal-title":"Leukemia"},{"key":"307_CR60","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/leu.2009.140","volume":"23","author":"S Bottcher","year":"2009","unstructured":"Bottcher S, Stilgenbauer S, Busch R, Bruggemann M, Raff T, Pott C, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia. 2009;23:2007\u201317.","journal-title":"Leukemia"},{"key":"307_CR61","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"307_CR62","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/leu.2013.52","volume":"27","author":"AC Logan","year":"2013","unstructured":"Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27:1659\u201365. \n                    https:\/\/doi.org\/10.1038\/leu.2013.52","journal-title":"Leukemia"},{"key":"307_CR63","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","volume":"116","author":"P Dreger","year":"2010","unstructured":"Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116:2438\u201347.","journal-title":"Blood"},{"key":"307_CR64","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/bmt.2015.150","volume":"50","author":"M Hahn","year":"2015","unstructured":"Hahn M, Bottcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P, et al. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. Bone Marrow Transplant. 2015;50:1279\u201385. \n                    https:\/\/doi.org\/10.1038\/bmt.2015.150\n                    \n                  . E-pub ahead of print 2015\/07\/07","journal-title":"Bone Marrow Transplant"},{"key":"307_CR65","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjh.12197","volume":"160","author":"SE Richardson","year":"2013","unstructured":"Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol. 2013;160:640\u20138. \n                    https:\/\/doi.org\/10.1111\/bjh.12197\n                    \n                  . E-pub ahead of print 2013\/01\/09","journal-title":"Br J Haematol"},{"key":"307_CR66","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","volume":"130","author":"I Kramer","year":"2017","unstructured":"Kramer I, Stilgenbauer S, Dietrich S, Bottcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130:1477\u201380. \n                    https:\/\/doi.org\/10.1182\/blood-2017-04-775841","journal-title":"Blood"},{"issue":"11","key":"307_CR67","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/leu.2017.96","volume":"31","author":"D R Howard","year":"2017","unstructured":"Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A et al. Results of the randomized phase IIB ARCTIC trial of low dose Rituximab in previously untreated CLL. Leukemia 2017. E-pub ahead of print 2017\/03\/25; \n                    https:\/\/doi.org\/10.1038\/leu.2017.96","journal-title":"Leukemia"},{"key":"307_CR68","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","volume":"30","author":"AR Pettitt","year":"2012","unstructured":"Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30:1647\u201355.","journal-title":"J Clin Oncol"},{"key":"307_CR69","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S Bottcher","year":"2012","unstructured":"Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch R, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression free and overall survival in chronic lymphocytic leukemia. A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980\u20138. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.36.9348","journal-title":"J Clin Oncol"},{"issue":"12","key":"307_CR70","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"Valentin Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1313984","journal-title":"New England Journal of Medicine"},{"key":"307_CR71","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","volume":"34","author":"G Kovacs","year":"2016","unstructured":"Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. J Clin Oncol. 2016;34:3758\u201365. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.67.1305","journal-title":"J Clin Oncol"},{"key":"307_CR72","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/s2352-3026(16)30045-x","volume":"3","author":"R Greil","year":"2016","unstructured":"Greil R, Obrtlikova P, Smolej L, Kozak T, Steurer M, Andel J, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a mabtenance randomised trial. Lancet Haematol. 2016;3:e317\u2013329. \n                    https:\/\/doi.org\/10.1016\/s2352-3026(16)30045-x\n                    \n                  . E-pub ahead of print 2016\/07\/05","journal-title":"Lancet Haematol"},{"key":"307_CR73","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","volume":"122","author":"M Ladetto","year":"2013","unstructured":"Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122:3759\u201366. \n                    https:\/\/doi.org\/10.1182\/blood-2013-06-507319\n                    \n                  . E-pub ahead of print 2013\/10\/03","journal-title":"Blood"},{"key":"307_CR74","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215\u201323. \n                    https:\/\/doi.org\/10.1182\/blood-2009-06-230250\n                    \n                  . E-pub ahead of print 2009\/12\/25","journal-title":"Blood"},{"key":"307_CR75","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(16)00739-x","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet. 2016;388:565\u201375. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(16)00739-x\n                    \n                  . E-pub ahead of print 2016\/06\/18","journal-title":"Lancet"},{"key":"307_CR76","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kruger","year":"2014","unstructured":"Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma\u2014final report from the prospective trials of the East German study group haematology\/oncology (OSHO). Ann Hematol. 2014;93:1587\u201397. \n                    https:\/\/doi.org\/10.1007\/s00277-014-2087-z\n                    \n                  . E-pub ahead of print 2014\/05\/02","journal-title":"Ann Hematol"},{"key":"307_CR77","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/bjh.14311","volume":"175","author":"AF Herrera","year":"2016","unstructured":"Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016;175:841\u201350. \n                    https:\/\/doi.org\/10.1111\/bjh.14311\n                    \n                  . E-pub ahead of print 2016\/10\/07","journal-title":"Br J Haematol"},{"key":"307_CR78","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3324\/haematol.2008.000273","volume":"94","author":"L Farina","year":"2009","unstructured":"Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica. 2009;94:654\u201362. \n                    https:\/\/doi.org\/10.3324\/haematol.2008.000273","journal-title":"Haematologica"},{"key":"307_CR79","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/ejh.12836","volume":"98","author":"C Algrin","year":"2017","unstructured":"Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, et al. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. Eur J Haematol. 2017;98:363\u201370. \n                    https:\/\/doi.org\/10.1111\/ejh.12836","journal-title":"Eur J Haematol"},{"key":"307_CR80","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","volume":"22","author":"T Flohr","year":"2008","unstructured":"Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771\u201382.","journal-title":"Leukemia"},{"key":"307_CR81","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.4049\/jimmunol.1201303","volume":"189","author":"K Larimore","year":"2012","unstructured":"Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol. 2012;189:3221\u201330. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1201303","journal-title":"J Immunol"},{"key":"307_CR82","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120:5173\u201380. \n                    https:\/\/doi.org\/10.1182\/blood-2012-07-444042\n                    \n                  . E-pub ahead of print 2012\/10\/18","journal-title":"Blood"},{"key":"307_CR83","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","volume":"111","author":"MJ Borowitz","year":"2008","unstructured":"Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group Study. Blood. 2008;111:5477\u201385.","journal-title":"Blood"},{"key":"307_CR84","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3109\/10428194.2016.1160080","volume":"57","author":"RD Cassaday","year":"2016","unstructured":"Cassaday RD, Alan Potts D Jr, Stevenson PA, Bar M, Georges GE, Shustov AR, et al. Evaluation of allogeneic transplantation in first or later minimal residual disease\u2014negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57:2109\u201318. \n                    https:\/\/doi.org\/10.3109\/10428194.2016.1160080","journal-title":"Leuk Lymphoma"},{"key":"307_CR85","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.bbmt.2016.07.021","volume":"22","author":"F Lussana","year":"2016","unstructured":"Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, et al. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 2016;22:1983\u20137. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.021","journal-title":"Biol Blood Marrow Transplant"},{"key":"307_CR86","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27:377\u201384.","journal-title":"J Clin Oncol"},{"key":"307_CR87","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1046\/j.1365-2141.2003.04394.x","volume":"122","author":"N Goulden","year":"2003","unstructured":"Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO, et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;122:24\u201329.","journal-title":"Br J Haematol"},{"key":"307_CR88","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","volume":"120","author":"W Leung","year":"2012","unstructured":"Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120:468\u201372. \n                    https:\/\/doi.org\/10.1182\/blood-2012-02-409813","journal-title":"Blood"},{"issue":"12","key":"307_CR89","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/leu.2012.123","volume":"26","author":"A Ruggeri","year":"2012","unstructured":"Ruggeri A, Michel G, Dalle JH, Caniglia M, Locatelli F, Campos A et al. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia 2012. E-pub ahead of print 2012\/05\/05; \n                    https:\/\/doi.org\/10.1038\/leu.2012.123","journal-title":"Leukemia"},{"key":"307_CR90","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.bbmt.2012.02.012","volume":"18","author":"V Bachanova","year":"2012","unstructured":"Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, et al. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant. 2012;18:963\u20138. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2012.02.012","journal-title":"Biol Blood Marrow Transplant"},{"key":"307_CR91","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","volume":"123","author":"MA Pulsipher","year":"2014","unstructured":"Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, et al. The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 children\u2019s oncology group\/pediatric blood and marrow transplant consortium trial. Blood. 2014;123:2017\u201325. \n                    https:\/\/doi.org\/10.1182\/blood-2013-10-534297","journal-title":"Blood"},{"key":"307_CR92","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/bmt.2015.103","volume":"50","author":"MA Pulsipher","year":"2015","unstructured":"Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll W, et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant. 2015;50:1173\u20139. \n                    https:\/\/doi.org\/10.1038\/bmt.2015.103","journal-title":"Bone Marrow Transplant"},{"key":"307_CR93","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bjh.12639","volume":"164","author":"A Balduzzi","year":"2014","unstructured":"Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A. et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. Br J Haematol. 2014;164:396\u2013408. \n                    https:\/\/doi.org\/10.1111\/bjh.12639\n                    \n                  . E-pub ahead of print 738 2014\/01\/16.","journal-title":"Br J Haematol"},{"key":"307_CR94","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015;33:1275\u201384. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.58.4631","journal-title":"J Clin Oncol"},{"key":"307_CR95","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.13142","volume":"168","author":"R Sutton","year":"2015","unstructured":"Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T, et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015;168:395\u2013404. \n                    https:\/\/doi.org\/10.1111\/bjh.13142","journal-title":"Br J Haematol"},{"key":"307_CR96","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2016.10.006","volume":"23","author":"E Rettinger","year":"2017","unstructured":"Rettinger E, Merker M, Salzmann-Manrique E, Kreyenberg H, Krenn T, Durken M, et al. Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2017;23:87\u201395. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2016.10.006","journal-title":"Biol Blood Marrow Transplant"},{"key":"307_CR97","doi-asserted-by":"publisher","first-page":"134ra163","DOI":"10.1126\/scitranslmed.3003656","volume":"4","author":"D Wu","year":"2012","unstructured":"Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med. 2012;4:134ra163 \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3003656","journal-title":"Sci Transl Med"},{"key":"307_CR98","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","volume":"20","author":"D Wu","year":"2014","unstructured":"Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:4540\u20138. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3231","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"307_CR99","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","volume":"125","author":"MA Pulsipher","year":"2015","unstructured":"Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015;125:3501\u20138. \n                    https:\/\/doi.org\/10.1182\/blood-2014-12-615757","journal-title":"Blood"},{"issue":"9","key":"307_CR100","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","volume":"20","author":"Aaron C. Logan","year":"2014","unstructured":"Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buno I et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant 2014. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2014.04.018","journal-title":"Biology of Blood and Marrow Transplantation"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0307-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:54Z","timestamp":1684617174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0307-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0307-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"13 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}